BI's 'Pradaxa antidote' idarucizumab wins US priority review
This article was originally published in Scrip
Executive Summary
The FDA has granted a priority review to Boehringer Ingelheim's biologics license application (BLA) for idarucizumab as an agent to reverse the anticoagulant effect of the firm's blood-thinning agent Pradaxa (dabigatran).